Jean Jacques Bienaime - Mar 10, 2023 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Chief Executive Officer, Director
Signature
/s/ Eric Fleekop, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
Mar 10, 2023
Transactions value $
-$548,170
Form type
4
Date filed
3/14/2023, 07:40 PM
Previous filing
Mar 2, 2023
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock Options Exercise $1.02M +15K +3.07% $67.81 503K Mar 10, 2023 Direct F1
transaction BMRN Common Stock Sale -$1.38M -15K -2.98% $92.28 488K Mar 10, 2023 Direct F1
transaction BMRN Common Stock Options Exercise $542K +8K +1.64% $67.81 496K Mar 13, 2023 Direct F2
transaction BMRN Common Stock Sale -$724K -8K -1.61% $90.45 488K Mar 13, 2023 Direct F2
holding BMRN Common Stock 247K Mar 10, 2023 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 Mar 10, 2023 Shares held as UTMA custodian for child
holding BMRN Common Stock 100 Mar 10, 2023 Shares held as UTMA custodian for child

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -15K -8.71% $0.00 157K Mar 10, 2023 Common Stock 15K $67.81 Direct F1, F3
transaction BMRN Stock Option (Right to buy Common Stock) Options Exercise $0 -8K -5.09% $0.00 149K Mar 13, 2023 Common Stock 8K $67.81 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on May 3, 2022.
F2 Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
F3 Reflects the number of options outstanding after the transactions from this specific stock option grant.